John Scarlett
Vorstandsvorsitzender bei GERON CORPORATION
Vermögen: 2 Mio $ am 30.04.2024
Profil
John A.
Scarlett was the founder of Sensus Drug Development Corp.
(founded in 1993) where he served as President & Chief Executive Officer from 1993 to 2001.
He was also the founder of Tercica, Inc. (founded in 2002) where he held the position of Chief Executive Officer & Director from 2007 to 2008.
Additionally, Dr. Scarlett founded Covance Biotechnology Services, Inc. (founded in 1995) and served as a Director from 1995 to 2000.
Dr. Scarlett is also the founder of Labcorp Drug Development, Inc. Dr. Scarlett's current job is Chairman, President & Chief Executive Officer at Geron Corp.
since 2011.
Among his former positions, he was President & Chief Executive Officer at Proteolix, Inc. in 2009, Independent Director at Chiasma, Inc. from 2015 to 2021, Director-Medical Research & Services at Ortho-McNeil Pharmaceutical LLC from 1982 to 1985, Independent Director at CytomX Therapeutics, Inc. from 2016 to 2022, Vice President-Clinical Affairs at Greenwich Pharmaceuticals, Inc. from 1985 to 1990, and Senior Vice President-Medical & Scientific Affairs at Novo Nordisk Pharmaceutical Industries, Inc. from 1991 to 1993.
Dr. Scarlett's education includes an undergraduate degree from Earlham College and a doctorate degree from Pritzker School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GERON CORPORATION
0,10% | 04.06.2024 | 600 000 ( 0,10% ) | 2 Mio $ | 30.04.2024 |
Aktive Positionen von John Scarlett
| Unternehmen | Position | Beginn |
|---|---|---|
| GERON CORPORATION | Vorstandsvorsitzender | 30.09.2011 |
Ehemalige bekannte Positionen von John Scarlett
| Unternehmen | Position | Ende |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.06.2022 |
| CHIASMA, INC. | Direktor/Vorstandsmitglied | 05.08.2021 |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Vorstandsvorsitzender | 01.11.2009 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Gründer | 17.10.2008 |
Sensus Drug Development Corp.
 Sensus Drug Development Corp. Pharmaceuticals: OtherHealth Technology Part of Pfizer Inc., Sensus Drug Development Corp. is a company that develops drugs to treat endocrine disorders. The company is based in San Antonio, TX. The company was founded by John A. Scarlett, Richard J. Hawkins. Sensus Drug Development was acquired by Pharmacia Corp. on March 07, 2001. | Vorstandsvorsitzender | 01.05.2001 |
Ausbildung von John Scarlett
| Earlham College | Undergraduate Degree |
| Pritzker School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Health Technology |
Sensus Drug Development Corp.
Sensus Drug Development Corp. Pharmaceuticals: OtherHealth Technology Part of Pfizer Inc., Sensus Drug Development Corp. is a company that develops drugs to treat endocrine disorders. The company is based in San Antonio, TX. The company was founded by John A. Scarlett, Richard J. Hawkins. Sensus Drug Development was acquired by Pharmacia Corp. on March 07, 2001. | Health Technology |
Novo Nordisk Pharmaceutical Industries, Inc.
 Novo Nordisk Pharmaceutical Industries, Inc. Pharmaceuticals: MajorHealth Technology Part of Novo Nordisk A/S, Novo Nordisk Pharmaceutical Industries, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Clayton, NC. | Health Technology |
Greenwich Pharmaceuticals, Inc.
 Greenwich Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Greenwich Pharmaceuticals, Inc. is an American company that specializes in commercial physical research. | Commercial Services |
Ortho-McNeil Pharmaceutical LLC
 Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ. | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Chiasma, Inc.
 Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Labcorp Drug Development, Inc.
 Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
